Bessemer Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Bessemer Group’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-153	Closed	-$20K	–	2686
2025 Q1	$20K	Buy	+153	New	+$19.1K	﹤0.01%	1549
2024 Q3	–	Sell	-115	Closed	-$8K	–	2725
2024 Q2	$8K	Buy	+115	New	+$7.98K	﹤0.01%	1596

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Bessemer Group's ITCI Position: Q2 2025 in Review

Bessemer Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 153 shares — an estimated $20K sold.

Bessemer Group first reported a position in ITCI in Q2 2024 and held it in 2 quarters. The position peaked at $20K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Bessemer Group reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Bessemer Group sold 153 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $20K.
Bessemer Group first reported a position in Intra-Cellular Therapies Inc. in Q2 2024 and held it in 2 quarters.
Bessemer Group's Intra-Cellular Therapies Inc. position peaked at $20K in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Bessemer Group's 13F filing for Q2 2025, filed 1 Aug 2025.